ADA 2021 | SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes | diabetes.medicinematters.com Skip to main content

06-29-2021 | ADA 2021 | Conference coverage | Video

SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes

share
SHARE

Michelle Welch discusses the positive glycemic and weight loss findings for tirzepatide versus placebo in people with insulin-dependent type 2 diabetes in SURPASS-5 (5:13).

Related content

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity